Market closedNon-fractional

Reneo Pharmaceuticals/RPHM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Reneo Pharmaceuticals

Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.

Ticker

RPHM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Irvine, United States

Employees

8

RPHM Metrics

BasicAdvanced
$50M
Market cap
-
P/E ratio
-$2.16
EPS
0.23
Beta
-
Dividend rate
$50M
0.23
29.825
29.437
0.709
1.116
-51.66%
-84.01%
0.62
0.62
-0.649
-1.60%
-41.71%

What the Analysts think about RPHM

Analyst Ratings

Majority rating from 3 analysts.
Hold

RPHM Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$8.4M
-64.26%
Profit margin
0.00%
NaN%

RPHM Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 42.75%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.65
-$0.57
-$0.71
-$0.25
-
Expected
-$0.52
-$0.57
-$0.58
-$0.44
-$0.10
Surprise
25.81%
-0.25%
22.88%
-42.75%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Reneo Pharmaceuticals stock?

Reneo Pharmaceuticals (RPHM) has a market cap of $50M as of July 06, 2024.

What is the P/E ratio for Reneo Pharmaceuticals stock?

The price to earnings (P/E) ratio for Reneo Pharmaceuticals (RPHM) stock is 0 as of July 06, 2024.

Does Reneo Pharmaceuticals stock pay dividends?

No, Reneo Pharmaceuticals (RPHM) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Reneo Pharmaceuticals dividend payment date?

Reneo Pharmaceuticals (RPHM) stock does not pay dividends to its shareholders.

What is the beta indicator for Reneo Pharmaceuticals?

Reneo Pharmaceuticals (RPHM) has a beta rating of 0.23. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Reneo Pharmaceuticals stock

Buy or sell Reneo Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing